APA (7th ed.) Citation

DR, C., F, B., JW, G., D, M., R, H., E, V., . . . K, K. (2023). Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(5), 1105. https://doi.org/10.1200/JCO.22.00739

Chicago Style (17th ed.) Citation

DR, Camidge, et al. "Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With C-Met Protein-Expressing Non-Small-Cell Lung Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 41, no. 5 (2023): 1105. https://doi.org/10.1200/JCO.22.00739.

MLA (9th ed.) Citation

DR, Camidge, et al. "Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With C-Met Protein-Expressing Non-Small-Cell Lung Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 41, no. 5, 2023, p. 1105, https://doi.org/10.1200/JCO.22.00739.